Treatment of Immune-Mediated TTP (iTTP) at the First Acute Event

Immune-mediated thrombotic thrombocytopenic purpura (iTTP) presenting as a first acute event is a medical emergency requiring a structured, evidence-based approach. This page outlines the clinical context and points to the complete treatment protocol.

Clinical Scenario

The patient has immune-mediated thrombotic thrombocytopenic purpura (iTTP) and is experiencing their first acute episode. This specific population — iTTP at first acute presentation — is the focus of the protocol referenced here.

Treatment Approach (Partial Overview)

Management of this presentation is built around therapeutic plasma exchange (TPE), with current evidence supporting a combination approach that adds immunosuppressive therapy and a targeted agent suitable for subcutaneous administration. The complete regimen — including all components, their sequencing, and clinical decision points — is available in the full protocol.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1111/jth.15010

For patients with iTTP experiencing a first acute event, the panel recommends the addition of corticosteroids to therapeutic plasma exchange (TPE) over TPE alone.
For patients with iTTP experiencing an acute event (first event or relapse), the panel suggests using caplacizumab over not using caplacizumab.
Drug acceptability would likely be reasonable because caplacizumab can be administered subcutaneously in an outpatient or home setting via self-administration.

View source ↗